EA039392B1 - Способ лечения рака с применением замещенного аминопуринового соединения - Google Patents
Способ лечения рака с применением замещенного аминопуринового соединения Download PDFInfo
- Publication number
- EA039392B1 EA039392B1 EA201892229A EA201892229A EA039392B1 EA 039392 B1 EA039392 B1 EA 039392B1 EA 201892229 A EA201892229 A EA 201892229A EA 201892229 A EA201892229 A EA 201892229A EA 039392 B1 EA039392 B1 EA 039392B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- compound
- patient
- treatment
- aminopurine compound
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 467
- 201000011510 cancer Diseases 0.000 title claims abstract description 278
- 238000000034 method Methods 0.000 title claims abstract description 207
- -1 aminopurine compound Chemical class 0.000 title claims description 261
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 81
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 76
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 53
- 208000032839 leukemia Diseases 0.000 claims abstract description 52
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 42
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 42
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 37
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 37
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 36
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 36
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 34
- 201000005202 lung cancer Diseases 0.000 claims abstract description 34
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 34
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 28
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 25
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 25
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 25
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 25
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 19
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 18
- 201000007270 liver cancer Diseases 0.000 claims abstract description 16
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 208000006265 Renal cell carcinoma Diseases 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 9
- 230000035772 mutation Effects 0.000 claims description 82
- 108060000903 Beta-catenin Proteins 0.000 claims description 61
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 60
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 60
- 102000015735 Beta-catenin Human genes 0.000 claims description 57
- 230000001965 increasing effect Effects 0.000 claims description 38
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 37
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 37
- 230000000694 effects Effects 0.000 claims description 33
- 230000019491 signal transduction Effects 0.000 claims description 28
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 24
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 24
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 24
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 11
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 11
- 102100039788 GTPase NRas Human genes 0.000 claims description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 8
- 102200055451 rs121913361 Human genes 0.000 claims description 4
- 238000011282 treatment Methods 0.000 abstract description 186
- 210000004027 cell Anatomy 0.000 description 202
- 229940125904 compound 1 Drugs 0.000 description 157
- 239000012472 biological sample Substances 0.000 description 124
- 210000000777 hematopoietic system Anatomy 0.000 description 115
- 201000001441 melanoma Diseases 0.000 description 111
- 230000014509 gene expression Effects 0.000 description 109
- 206010025323 Lymphomas Diseases 0.000 description 97
- 108090000623 proteins and genes Proteins 0.000 description 83
- 108020004999 messenger RNA Proteins 0.000 description 82
- 230000003902 lesion Effects 0.000 description 71
- 210000002429 large intestine Anatomy 0.000 description 70
- 150000001875 compounds Chemical class 0.000 description 68
- 230000004044 response Effects 0.000 description 67
- 210000004072 lung Anatomy 0.000 description 65
- 102000004169 proteins and genes Human genes 0.000 description 65
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 62
- 206010039491 Sarcoma Diseases 0.000 description 46
- 210000003739 neck Anatomy 0.000 description 45
- 210000004872 soft tissue Anatomy 0.000 description 45
- 230000005764 inhibitory process Effects 0.000 description 44
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 44
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 44
- 210000003128 head Anatomy 0.000 description 43
- 210000004185 liver Anatomy 0.000 description 43
- 239000000090 biomarker Substances 0.000 description 42
- 210000003169 central nervous system Anatomy 0.000 description 42
- 206010018338 Glioma Diseases 0.000 description 41
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 41
- 208000032612 Glial tumor Diseases 0.000 description 40
- 230000007423 decrease Effects 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 210000005075 mammary gland Anatomy 0.000 description 36
- 101000759453 Homo sapiens YY1-associated protein 1 Proteins 0.000 description 35
- 102100023267 YY1-associated protein 1 Human genes 0.000 description 35
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 description 32
- 101001057587 Homo sapiens Dual specificity protein phosphatase 6 Proteins 0.000 description 32
- 201000010099 disease Diseases 0.000 description 32
- 210000000496 pancreas Anatomy 0.000 description 31
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 29
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 29
- 210000004907 gland Anatomy 0.000 description 29
- 201000008968 osteosarcoma Diseases 0.000 description 28
- 108091054455 MAP kinase family Proteins 0.000 description 27
- 102000043136 MAP kinase family Human genes 0.000 description 27
- 238000001574 biopsy Methods 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 208000030381 cutaneous melanoma Diseases 0.000 description 25
- 201000003708 skin melanoma Diseases 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 108090001007 Interleukin-8 Proteins 0.000 description 24
- 102000004890 Interleukin-8 Human genes 0.000 description 24
- 201000005787 hematologic cancer Diseases 0.000 description 24
- 230000004083 survival effect Effects 0.000 description 24
- 230000002485 urinary effect Effects 0.000 description 24
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 23
- 108010058546 Cyclin D1 Proteins 0.000 description 23
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 23
- 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 23
- 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 239000003981 vehicle Substances 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 210000003734 kidney Anatomy 0.000 description 21
- 102100035683 Axin-2 Human genes 0.000 description 20
- 101700047552 Axin-2 Proteins 0.000 description 20
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 20
- 230000000259 anti-tumor effect Effects 0.000 description 20
- 208000003747 lymphoid leukemia Diseases 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 230000037396 body weight Effects 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 18
- 201000000050 myeloid neoplasm Diseases 0.000 description 18
- 230000009467 reduction Effects 0.000 description 18
- 238000003753 real-time PCR Methods 0.000 description 17
- 210000000130 stem cell Anatomy 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 101001078211 Homo sapiens Izumo sperm-egg fusion protein 2 Proteins 0.000 description 16
- 102100025318 Izumo sperm-egg fusion protein 2 Human genes 0.000 description 16
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- 210000003679 cervix uteri Anatomy 0.000 description 16
- 230000034994 death Effects 0.000 description 16
- 231100000517 death Toxicity 0.000 description 16
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 16
- 238000002600 positron emission tomography Methods 0.000 description 16
- 208000037821 progressive disease Diseases 0.000 description 16
- 210000001685 thyroid gland Anatomy 0.000 description 16
- 102100038778 Amphiregulin Human genes 0.000 description 15
- 101000809450 Homo sapiens Amphiregulin Proteins 0.000 description 15
- 206010029260 Neuroblastoma Diseases 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 15
- 108050003627 Wnt Proteins 0.000 description 15
- 230000036961 partial effect Effects 0.000 description 15
- 230000002265 prevention Effects 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 206010005003 Bladder cancer Diseases 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 102100031168 CCN family member 2 Human genes 0.000 description 14
- 102100028914 Catenin beta-1 Human genes 0.000 description 14
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 14
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 14
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 14
- 208000024770 Thyroid neoplasm Diseases 0.000 description 14
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 14
- 230000002124 endocrine Effects 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- 102200055464 rs113488022 Human genes 0.000 description 14
- 201000002510 thyroid cancer Diseases 0.000 description 14
- 201000005112 urinary bladder cancer Diseases 0.000 description 14
- 102100021670 Bcl-2-modifying factor Human genes 0.000 description 13
- 102100031171 CCN family member 1 Human genes 0.000 description 13
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 description 13
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 13
- 102100027088 Dual specificity protein phosphatase 5 Human genes 0.000 description 13
- 102100039577 ETS translocation variant 5 Human genes 0.000 description 13
- 102100023226 Early growth response protein 1 Human genes 0.000 description 13
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 13
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 13
- 101000896211 Homo sapiens Bcl-2-modifying factor Proteins 0.000 description 13
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 description 13
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 description 13
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 description 13
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 13
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 13
- 101000629617 Homo sapiens Protein sprouty homolog 4 Proteins 0.000 description 13
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 13
- 102100027584 Protein c-Fos Human genes 0.000 description 13
- 102100026845 Protein sprouty homolog 4 Human genes 0.000 description 13
- 210000001672 ovary Anatomy 0.000 description 13
- 229920002477 rna polymer Polymers 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 102100035079 ETS-related transcription factor Elf-3 Human genes 0.000 description 12
- 108010043945 Ephrin-A1 Proteins 0.000 description 12
- 102000020086 Ephrin-A1 Human genes 0.000 description 12
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 12
- 101000877379 Homo sapiens ETS-related transcription factor Elf-3 Proteins 0.000 description 12
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 description 12
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 12
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 12
- 101000962469 Homo sapiens Transcription factor MafF Proteins 0.000 description 12
- 208000008839 Kidney Neoplasms Diseases 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 12
- 208000032383 Soft tissue cancer Diseases 0.000 description 12
- 102100030798 Transcription factor HES-1 Human genes 0.000 description 12
- 102100039187 Transcription factor MafF Human genes 0.000 description 12
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 12
- 201000007455 central nervous system cancer Diseases 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 208000014829 head and neck neoplasm Diseases 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 108090000397 Caspase 3 Proteins 0.000 description 11
- 102100029855 Caspase-3 Human genes 0.000 description 11
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 11
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 11
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 11
- 101710085938 Matrix protein Proteins 0.000 description 11
- 101710127721 Membrane protein Proteins 0.000 description 11
- 206010038389 Renal cancer Diseases 0.000 description 11
- 206010041067 Small cell lung cancer Diseases 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 201000010982 kidney cancer Diseases 0.000 description 11
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 208000000587 small cell lung carcinoma Diseases 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 210000002229 urogenital system Anatomy 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- 108010085238 Actins Proteins 0.000 description 10
- 101100239628 Danio rerio myca gene Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 208000000172 Medulloblastoma Diseases 0.000 description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 238000011579 SCID mouse model Methods 0.000 description 10
- 201000005188 adrenal gland cancer Diseases 0.000 description 10
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000003394 haemopoietic effect Effects 0.000 description 10
- 201000010536 head and neck cancer Diseases 0.000 description 10
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 9
- 102100032965 Myomesin-2 Human genes 0.000 description 9
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 9
- 206010047741 Vulval cancer Diseases 0.000 description 9
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 9
- 230000001028 anti-proliverative effect Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 230000005757 colony formation Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 230000002459 sustained effect Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 201000005102 vulva cancer Diseases 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 229960004066 trametinib Drugs 0.000 description 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 7
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 7
- 206010033128 Ovarian cancer Diseases 0.000 description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 208000002495 Uterine Neoplasms Diseases 0.000 description 7
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 201000010881 cervical cancer Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 230000005750 disease progression Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 230000002489 hematologic effect Effects 0.000 description 7
- 230000017945 hippo signaling cascade Effects 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 201000000849 skin cancer Diseases 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 206010046766 uterine cancer Diseases 0.000 description 7
- UQOKRDJILZMZKU-UHFFFAOYSA-N 2-nitropyrimidine Chemical class [O-][N+](=O)C1=NC=CC=N1 UQOKRDJILZMZKU-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 206010073130 Central nervous system neuroblastoma Diseases 0.000 description 6
- 206010061825 Duodenal neoplasm Diseases 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102100030708 GTPase KRas Human genes 0.000 description 6
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 6
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 208000000453 Skin Neoplasms Diseases 0.000 description 6
- 206010054184 Small intestine carcinoma Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 201000001403 cerebral neuroblastoma Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 201000000312 duodenum cancer Diseases 0.000 description 6
- 201000004101 esophageal cancer Diseases 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 208000005017 glioblastoma Diseases 0.000 description 6
- 230000000155 isotopic effect Effects 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 description 5
- 206010057644 Testis cancer Diseases 0.000 description 5
- 230000004156 Wnt signaling pathway Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000006882 induction of apoptosis Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 210000004180 plasmocyte Anatomy 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 201000003120 testicular cancer Diseases 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 210000003905 vulva Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 238000001061 Dunnett's test Methods 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 4
- 150000005005 aminopyrimidines Chemical class 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000002784 cytotoxicity assay Methods 0.000 description 4
- 231100000263 cytotoxicity test Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 238000001543 one-way ANOVA Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 102200044943 rs121913400 Human genes 0.000 description 4
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 230000004797 therapeutic response Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108090000567 Caspase 7 Proteins 0.000 description 3
- 102100038902 Caspase-7 Human genes 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 239000012824 ERK inhibitor Substances 0.000 description 3
- 206010064571 Gene mutation Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 208000008771 Lymphadenopathy Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 102100038123 Teneurin-4 Human genes 0.000 description 3
- 101710122302 Teneurin-4 Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 108010004469 allophycocyanin Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 208000027124 goblet cell carcinoma Diseases 0.000 description 3
- 208000029824 high grade glioma Diseases 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000011614 malignant glioma Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 102220198036 rs121913400 Human genes 0.000 description 3
- 102200044940 rs28931589 Human genes 0.000 description 3
- 102220006067 rs587776850 Human genes 0.000 description 3
- 208000011581 secondary neoplasm Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- RZUOCXOYPYGSKL-GOSISDBHSA-N 1-[(1s)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-[2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]pyridin-2-one Chemical compound CN1N=CC=C1NC1=NC=CC(C2=CC(=O)N([C@H](CO)C=3C=C(F)C(Cl)=CC=3)C=C2)=N1 RZUOCXOYPYGSKL-GOSISDBHSA-N 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 2
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical class NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 2
- 101000825960 Homo sapiens R-spondin-3 Proteins 0.000 description 2
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102100020870 La-related protein 6 Human genes 0.000 description 2
- 108050008265 La-related protein 6 Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 102100022766 R-spondin-3 Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 101100004606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BPH1 gene Proteins 0.000 description 2
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000005018 aminopurines Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000010293 colony formation assay Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000001 growth retardation Toxicity 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000006712 oncogenic signaling pathway Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102200006539 rs121913529 Human genes 0.000 description 2
- 102200082402 rs751610198 Human genes 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OOKAZRDERJMRCJ-KOUAFAAESA-N (3r)-7-[(1s,2s,4ar,6s,8s)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl]-3-hydroxy-5-oxoheptanoic acid Chemical compound C1=C[C@H](C)[C@H](CCC(=O)C[C@@H](O)CC(O)=O)C2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C[C@@H]21 OOKAZRDERJMRCJ-KOUAFAAESA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- AOYNUTHNTBLRMT-SLPGGIOYSA-N 2-deoxy-2-fluoro-aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](F)C=O AOYNUTHNTBLRMT-SLPGGIOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- UDPBBKMADGQOBX-UHFFFAOYSA-N 4-aminocyclohexane-1-carboxamide Chemical class NC1CCC(C(N)=O)CC1 UDPBBKMADGQOBX-UHFFFAOYSA-N 0.000 description 1
- DRNGLYHKYPNTEA-UHFFFAOYSA-N 4-azaniumylcyclohexane-1-carboxylate Chemical class NC1CCC(C(O)=O)CC1 DRNGLYHKYPNTEA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101150042405 CCN1 gene Proteins 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 101100327819 Caenorhabditis elegans chl-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 206010007270 Carcinoid syndrome Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229910021554 Chromium(II) chloride Inorganic materials 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000722210 Homo sapiens ATP-dependent DNA helicase DDX11 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101001093139 Homo sapiens MAU2 chromatid cohesion factor homolog Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101001112222 Homo sapiens Neural cell adhesion molecule L1-like protein Proteins 0.000 description 1
- 101001126102 Homo sapiens Pleckstrin homology domain-containing family B member 1 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 101710110822 L-histidine 2-aminobutanoyltransferase Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100036309 MAU2 chromatid cohesion factor homolog Human genes 0.000 description 1
- 241001108995 Messa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 1
- 208000006066 Neoplasms by Site Diseases 0.000 description 1
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 1
- 101100058191 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) bcp-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108090001145 Nuclear Receptor Coactivator 3 Proteins 0.000 description 1
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000595993 Phyllomedusa sauvagei Phylloseptin-S1 Proteins 0.000 description 1
- 101000927341 Pithecopus azureus Dermaseptin-H5 Proteins 0.000 description 1
- 101100352419 Pithecopus hypochondrialis psn1 gene Proteins 0.000 description 1
- 102100030462 Pleckstrin homology domain-containing family B member 1 Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101100331535 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) DIB1 gene Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000030317 anaplastic cancer Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005735 apoptotic response Effects 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 101150038746 bcp1 gene Proteins 0.000 description 1
- 101150023633 bcpB gene Proteins 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 208000025188 carcinoma of pharynx Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- XBWRJSSJWDOUSJ-UHFFFAOYSA-L chromium(ii) chloride Chemical compound Cl[Cr]Cl XBWRJSSJWDOUSJ-UHFFFAOYSA-L 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical group NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 101150042537 dld1 gene Proteins 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002075 inversion recovery Methods 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037843 metastatic solid tumor Diseases 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000025 natural resin Substances 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000016632 ovarian clear cell cancer Diseases 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000008814 placenta cancer Diseases 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 102200006562 rs104894231 Human genes 0.000 description 1
- 102200006532 rs112445441 Human genes 0.000 description 1
- 102200006520 rs121913240 Human genes 0.000 description 1
- 102200006531 rs121913529 Human genes 0.000 description 1
- 102200006538 rs121913530 Human genes 0.000 description 1
- 102200004971 rs62638630 Human genes 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317412P | 2016-04-01 | 2016-04-01 | |
| PCT/US2017/025252 WO2017173206A1 (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201892229A1 EA201892229A1 (ru) | 2019-03-29 |
| EA039392B1 true EA039392B1 (ru) | 2022-01-21 |
Family
ID=59959573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892229A EA039392B1 (ru) | 2016-04-01 | 2017-03-31 | Способ лечения рака с применением замещенного аминопуринового соединения |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10576085B2 (enExample) |
| EP (1) | EP3436018A4 (enExample) |
| JP (1) | JP7014731B2 (enExample) |
| KR (1) | KR102356433B1 (enExample) |
| CN (1) | CN109069512B (enExample) |
| AU (1) | AU2017241837B2 (enExample) |
| BR (1) | BR112018070163A2 (enExample) |
| CA (1) | CA3018986A1 (enExample) |
| CL (1) | CL2018002787A1 (enExample) |
| EA (1) | EA039392B1 (enExample) |
| IL (1) | IL262007B2 (enExample) |
| MX (1) | MX379513B (enExample) |
| NZ (1) | NZ746554A (enExample) |
| SG (2) | SG11201808388QA (enExample) |
| WO (1) | WO2017173206A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| WO2017167953A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| HRP20210847T1 (hr) | 2016-03-31 | 2021-07-23 | Janssen Pharmaceuticals, Inc. | Supstituirani derivati indola kao inhibitori replikacije denga virusa |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
| MX379439B (es) | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3060583C (en) | 2017-05-22 | 2024-06-04 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| CR20190531A (es) | 2017-05-22 | 2020-03-05 | Janssen Pharmaceuticals Inc | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
| MX2020003620A (es) | 2017-10-04 | 2020-10-28 | Celgene Corp | Composiciones y métodos para usar cis-4-[2-{[(3s,4r)-3-fluorooxan- 4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-etilcicloh exano-1-carboxamida. |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| EP3833372A4 (en) * | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| AU2020257207B2 (en) * | 2019-04-16 | 2026-06-04 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| PH12022551160A1 (en) | 2019-11-15 | 2023-09-25 | Janssen Pharmaceuticals Inc | Treatment and prevention of dengue disease |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| KR102664454B1 (ko) * | 2021-08-03 | 2024-05-09 | 한국생명공학연구원 | 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용 |
| CN114681456A (zh) * | 2022-02-23 | 2022-07-01 | 中山大学附属第六医院 | Plx3397在结直肠癌的治疗中的用途 |
| EP4703725A1 (en) | 2024-08-29 | 2026-03-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070142405A1 (en) * | 2003-12-23 | 2007-06-21 | Qing Dong | Bicyclic heterocyclic p-38 kinase inhibitors |
| US20100016586A1 (en) * | 2006-05-12 | 2010-01-21 | Myriad Genetics, Incorporated | Therapeutic compounds and their use in cancer |
| US20130225564A1 (en) * | 2005-01-13 | 2013-08-29 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof,and methods of treatment therewith |
| US20160096841A1 (en) * | 2014-10-06 | 2016-04-07 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| WO2007062338A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| NZ576347A (en) | 2006-10-27 | 2011-10-28 | Signal Pharm Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and use therewith |
| DK2279731T3 (da) | 2008-04-23 | 2013-03-18 | Farmasierra Mfg S L | Forbedret farmaceutisk sammensætning, som indeholder ibuprofen og codein |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
| WO2014172616A2 (en) | 2013-04-18 | 2014-10-23 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| CN115131834A (zh) * | 2015-08-13 | 2022-09-30 | 小米科技有限责任公司 | 移动设备及其屏幕模组、指纹采集方法、装置及电子设备 |
| MX379439B (es) * | 2016-04-01 | 2025-03-10 | Signal Pharm Llc | Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1-metilciclohexano-1-carboxamida y métodos para utilizarlas. |
-
2017
- 2017-03-31 US US15/475,899 patent/US10576085B2/en active Active
- 2017-03-31 EA EA201892229A patent/EA039392B1/ru unknown
- 2017-03-31 MX MX2018011992A patent/MX379513B/es unknown
- 2017-03-31 KR KR1020187028514A patent/KR102356433B1/ko active Active
- 2017-03-31 CN CN201780021651.0A patent/CN109069512B/zh active Active
- 2017-03-31 WO PCT/US2017/025252 patent/WO2017173206A1/en not_active Ceased
- 2017-03-31 SG SG11201808388QA patent/SG11201808388QA/en unknown
- 2017-03-31 JP JP2018551358A patent/JP7014731B2/ja active Active
- 2017-03-31 EP EP17776735.7A patent/EP3436018A4/en not_active Withdrawn
- 2017-03-31 NZ NZ746554A patent/NZ746554A/en unknown
- 2017-03-31 SG SG10202009589UA patent/SG10202009589UA/en unknown
- 2017-03-31 BR BR112018070163A patent/BR112018070163A2/pt not_active Application Discontinuation
- 2017-03-31 CA CA3018986A patent/CA3018986A1/en not_active Abandoned
- 2017-03-31 AU AU2017241837A patent/AU2017241837B2/en active Active
- 2017-03-31 IL IL262007A patent/IL262007B2/en unknown
-
2018
- 2018-09-28 CL CL2018002787A patent/CL2018002787A1/es unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070142405A1 (en) * | 2003-12-23 | 2007-06-21 | Qing Dong | Bicyclic heterocyclic p-38 kinase inhibitors |
| US20130225564A1 (en) * | 2005-01-13 | 2013-08-29 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof,and methods of treatment therewith |
| US20100016586A1 (en) * | 2006-05-12 | 2010-01-21 | Myriad Genetics, Incorporated | Therapeutic compounds and their use in cancer |
| US20160096841A1 (en) * | 2014-10-06 | 2016-04-07 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019510066A (ja) | 2019-04-11 |
| WO2017173206A1 (en) | 2017-10-05 |
| IL262007B2 (en) | 2023-04-01 |
| IL262007A (en) | 2018-10-31 |
| SG11201808388QA (en) | 2018-10-30 |
| AU2017241837A1 (en) | 2018-10-25 |
| MX2018011992A (es) | 2019-01-24 |
| CN109069512A (zh) | 2018-12-21 |
| AU2017241837B2 (en) | 2021-07-22 |
| EP3436018A4 (en) | 2019-11-13 |
| KR20180126497A (ko) | 2018-11-27 |
| CL2018002787A1 (es) | 2019-01-18 |
| SG10202009589UA (en) | 2020-10-29 |
| US20170281633A1 (en) | 2017-10-05 |
| US10576085B2 (en) | 2020-03-03 |
| JP7014731B2 (ja) | 2022-02-01 |
| EA201892229A1 (ru) | 2019-03-29 |
| IL262007B (en) | 2022-12-01 |
| EP3436018A1 (en) | 2019-02-06 |
| BR112018070163A2 (pt) | 2019-01-29 |
| NZ746554A (en) | 2023-03-31 |
| CN109069512B (zh) | 2022-06-14 |
| CA3018986A1 (en) | 2017-10-05 |
| KR102356433B1 (ko) | 2022-01-27 |
| MX379513B (es) | 2025-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7014731B2 (ja) | 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法 | |
| ES2620644T3 (es) | Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso | |
| KR102615210B1 (ko) | 난소암의 치료에 사용되는 티노스타무스틴 | |
| US10513519B2 (en) | Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| US11337969B2 (en) | Methods for treating cancer | |
| JP6147246B2 (ja) | Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法 | |
| TW202425991A (zh) | 阿森色替於治療癌症中之間歇性給藥方案 | |
| EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
| US20220087946A1 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| CN117279639A (zh) | 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 | |
| US12319915B2 (en) | Cytotoxic fluoropyrimidine polymers and methods of use thereof | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| HK40131055A (en) | A pharmaceutical combination and use thereof | |
| TW202608446A (zh) | 依維替定（ｅｃｕｂｅｃｔｅｄｉｎ）於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 | |
| KR20260069685A (ko) | Mat2a 관련 질환을 치료하는 방법 | |
| HK40016954A (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| HK1233924A1 (en) | Derivatives of cephalosporin for treating cancer | |
| HK1233924B (en) | Derivatives of cephalosporin for treating cancer | |
| HK1193754A (en) | Combinations of akt and mek inhibitor compounds, and methods of use | |
| NZ629860B (en) | Methods for treating cancer using tor kinase inhibitor combination therapy |